Sage Therapeutics, Inc. (NASDAQ:SAGE) – Analysts at Piper Sandler issued their FY2026 EPS estimates for Sage Therapeutics in a research note issued to investors on Wednesday, January 12th. Piper Sandler analyst Y. Rahimi anticipates that the biopharmaceutical company will earn $14.91 per share for the year.
A number of other brokerages have also recently commented on SAGE. Needham & Company LLC upped their price target on shares of Sage Therapeutics from $79.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, January 6th. HC Wainwright decreased their target price on shares of Sage Therapeutics from $80.00 to $55.00 and set a “neutral” rating on the stock in a report on Wednesday, November 3rd. Jefferies Financial Group lowered shares of Sage Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $100.00 to $50.00 in a report on Wednesday, October 6th. Royal Bank of Canada decreased their target price on shares of Sage Therapeutics from $52.00 to $48.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 2nd. Finally, SVB Leerink decreased their target price on shares of Sage Therapeutics from $70.00 to $60.00 and set a “market perform” rating on the stock in a report on Monday, December 20th. Eleven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $70.29.
Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, November 2nd. The biopharmaceutical company reported ($2.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.84) by ($0.37). The business had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.00 million. Sage Therapeutics had a net margin of 57.61% and a negative return on equity of 23.76%. During the same quarter in the previous year, the company posted ($2.03) earnings per share.
Several large investors have recently bought and sold shares of the company. Diversified Trust Co purchased a new stake in shares of Sage Therapeutics in the 4th quarter worth about $215,000. Tributary Capital Management LLC lifted its position in shares of Sage Therapeutics by 95.0% in the 4th quarter. Tributary Capital Management LLC now owns 19,500 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 9,500 shares during the period. Hudson Bay Capital Management LP purchased a new stake in shares of Sage Therapeutics in the 3rd quarter worth about $1,108,000. BNP Paribas Arbitrage SA lifted its position in Sage Therapeutics by 147.3% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 4,845 shares of the biopharmaceutical company’s stock valued at $215,000 after acquiring an additional 2,886 shares during the period. Finally, UBS Group AG lifted its position in Sage Therapeutics by 261.5% during the 3rd quarter. UBS Group AG now owns 98,000 shares of the biopharmaceutical company’s stock valued at $4,342,000 after acquiring an additional 70,887 shares during the period. 86.94% of the stock is owned by hedge funds and other institutional investors.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders.
Read More: Neutral Rating
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.